- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04:13 | Leads Biolabs' IPO points to biotech rebound in Hong Kong | 2 | KrASIA | ||
| Fr | Chinese antibody developer Leads Biolabs hits Hong Kong stock exchange in $189M IPO | 2 | FierceBiotech | ||
| Fr | LEADS BIOLABS-B (09887): CHANGE IN COMPOSITION OF NOMINATION COMMITTEE AND APPOINTMENT OF LEAD INED | 1 | HKEx | ||
| NANJING LEADS BIOLABS Aktie jetzt für 0€ handeln | |||||
| Fr | LEADS BIOLABS-B Closes Up 91.7% to $67.1 | 1 | AASTOCKS | ||
| Fr | LEADS BIOLABS-B Closes Up 99% to $69.65 at Midday | 2 | AASTOCKS | ||
| Fr | LEADS BIOLABS-B Opens Up 106.9% to $72.4 on Debut | 1 | AASTOCKS | ||
| Fr | Leads Biolabs lists on HKEX, raises $189 million in IPO | 1 | Investing.com | ||
| Fr | Leads Biolabs Lists on HKEX, Raising USD 189 Million Through Initial Public Offering | 105 | PR Newswire | NANJING, China, July 24, 2025 /PRNewswire/ -- On 25 July, 2025 (China Time), Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company") listed on the... ► Artikel lesen | |
| 24.07. | LEADS BIOLABS-B (09887): ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS | - | HKEx | ||
| 24.07. | Leads Biolabs-B Closes Up 99.3% to $69.75 on Gray Mkt | 2 | AASTOCKS | ||
| 24.07. | Leads Biolabs-B Opens Up 38.9% to $48.6 on Gray Mkt | 1 | AASTOCKS | ||
| 24.07. | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE OF THE BOARD OF DIRECTORS | 2 | HKEx | ||
| 24.07. | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 24.07. | LEADS BIOLABS-B (09887): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 24.07. | LEADS BIOLABS-B (09887): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 24.07. | LEADS BIOLABS-B (09887): TERMS OF REFERENCE OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS | 1 | HKEx | ||
| 21.07. | LEADS BIOLABS-B (09887.HK) Records Margin Oversubscription 1,300x+ | 1 | AASTOCKS | ||
| 17.07. | LEADS BIOLABS-B IPO Starts Tdy w/Entry Fee HKD3,535.3; TENCENT Among Cornerstone Investors | 15 | AASTOCKS | ||
| 17.07. | LEADS BIOLABS-B (09887): GLOBAL OFFERING | 1 | HKEx |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 44,180 | -0,24 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EVOTEC | 7,378 | -0,30 % | Fast 200 % Kurspotenzial! Evotec, Plug Power, Empire Brand Building Aktie | Erstmals haben Analysten den Newcomer Empire Brand Building unter die Lupe genommen. Sie sehen bei dem Schweizer Betreiber von Social Media- und E-Commerce-Plattformen für Familien fast 200 % Kurspotenzial.... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 30,060 | -1,12 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution | - ARCALYST® (rilonacept) Q2 2025 net product revenue of $156.8 million, representing 52% year-over-year growth -- ARCALYST 2025 expected net product revenue increased to $625 - $640 million -- KPL-387... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 36,880 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,805 | 0,00 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
| IMMUNOME | 10,750 | +1,18 % | Immunome Inc. - 8-K, Current Report | ||
| BEAM THERAPEUTICS | 20,140 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,590 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 50,56 | 0,00 % | ROUNDUP/Aktien New York Schluss: Gewinne - Arbeitsmarktdaten stützen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Dienstag nach einem verhaltenen Start ihre Kursgewinne ausgebaut. Marktbeobachter verwiesen darauf, dass die jüngsten Daten vom US-Arbeitsmarkt trotz... ► Artikel lesen | |
| FULCRUM THERAPEUTICS | 6,900 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2025 | - Announced results from the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); pociredir was generally well-tolerated with no treatment-related serious... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 56,61 | +1,16 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,660 | 0,00 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| PTC THERAPEUTICS | 41,800 | 0,00 % | XFRA BH3: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILPTC THERAPEUTICS... ► Artikel lesen | |
| COGENT BIOSCIENCES | 11,540 | -2,45 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| CG ONCOLOGY | 26,950 | +3,49 % | CG Oncology wins Delaware jury trial against ANI Pharmaceuticals |
NANJING LEADS BIOLABS CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANJING LEADS BIOLABS CO LTD finden Sie auf Wallstreet Online.